Synthesis and Evaluation of 3-Methyl-4-oxo-6-phenyl-4,5,6,7-tetrahydrobenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Potent Antitumor Agents
For the construction of new combinatorial libraries, a lead compound was created by replacing the core structure of a hit compound discovered by screening for cytotoxic agents against a tumorigenic cell line. The newly designed compound maintained biological activity and allowed alternative library construction for antitumor drugs.
Key words antitumor; anticancer; cytotoxicity; 4,5,6,7-tetrahydrobenzofuran 1). The corresponding dimethoxyphenyl ketone (15), which was expected to be metabolically stable, 1) was converted from 7a (Chart 2). For the purpose of comparing the SAR of indole derivative 9a, 4,5,6,7-tetrahydro-1H-indole derivative 8a was also synthesized as shown in Chart 1.
The cytotoxicity of the synthesized derivatives and related compounds are summarized in Table 1 . The potency of compound 7a was stronger than corresponding benzofuran compound 1. A derivative with a fluorine substituent (7b) also possessed significant biological activity. These results indicate that 4,5,6,7-tetrahydrobenzofuran is an alternative core structure that shows selective cytotoxicity as benzofuran core. Nitrogen analogues (8a) 5) maintained cytotoxicity, nevertheless dimethoxyphenyl ketone (15) completely lost biological activity.
Although ketone derivative 15 was designed to avoid metabolic deactivation by the enzymatic hydrolysis of the ethyl ester and this was successful in the benzofuran derivatives, this approach was unfortunately revealed to be inapplicable to 4,5,6,7-tetrahydrobenzofuran derivatives.
In conclusion, 4,5,6,7-tetrahydrobenzofuran was recognized to be a new core structure for compound libraries targeting antitumor drugs. The derivatives based on this different core structure are expected to have different biological properties, which expand the possibilities to be new antitumor drugs.
Experimental
Melting points (mp) were determined with a Yanaco melting point apparatus and not corrected. Infrared (IR) spectra were measured with a Nic 5SXC FT-IR spectrophotometer. NMR spectra were recorded on a JEOL JNM-GX 270 FT-NMR or a Varian Mercury 400 spectrophotometer. Chemical shifts are expressed in d ppm from the internal standard tetramethylsilane (TMS). Mass spectra were obtained on a JEOL HX-100, SX-102A or JMS-AX-505H mass spectrometer instruments by applying an electric ionization (EI) method, a fast atom bombardment (FAB) ionization method, or an electrospray ionization (ESI) method. Column chromatography was carried out using SK-85 (230-400 mesh). Preparative thin-layer chromatography (PTLC) was performed using 60 F 254 plates (Merck art. 5744). Yields were not optimized.
Evaluation of Biological Activity Human tumorigenic cell line VA13 (CCL-75.1) and its parental normal cell line WI-38 (CCL-75) were obtained from the American Tissue Culture Collection (ATCC) and were maintained and assayed in Minimum Essential Medium-Eagle (MEM-E) with Earl's salts (11095-080, Gibco BRL) with 100 U/ml of penicillin and 100 mg/ml of streptomycin supplemented with 10% fetal calf serum (Hyclone). Exponentially growing VA-13 cells and WI-38 cells were collected and distributed into 96-well plates (3598, Corning-Coaster) at a density of 1.5-3.0ϫ10 3 cells and 4.8-9.6ϫ10 3 cells, respectively, at a final volume of 200 ml/well.
After cultivation for two or three days, test compounds dissolved in DMSO were diluted with fresh growth medium and then added to the plates. The final concentrations of DMSO were always kept at less than 0.5%. The plates were incubated for 24 h. Then the culture medium was removed and washed. Finally, 150 ml/well of fresh medium was added to the cells. After cultivation for three days, 50 ml/well of MEM-E containing 1 mg/ml of 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanide (XTT: X-4251, Sigma) and 25 mM of phenazine methosulfate (P-9625, Sigma) was added and the plates were incubated for 2.5 h. OD450 was measured by a SPECTRA MAX 250 (Molecular Devices) and cell viability was calculated using the following formula:
cell viability (%)ϭ(WCϪBG)ϫ100/(RFϪBG) WC: OD450 for well containing cells treated with compounds RF: OD450 for well containing cells and no compounds BG: OD450 for well containing neither cells nor compounds A dose-response curve was drawn and the 50% effective concentration (EC 50 ) was determined as an indicator of compound cytotoxicity.
3-Methyl-4-oxo-6-phenyl-4,5,6,7-tetrahydrobenzofuran-2-carboxylic Acid Ethyl Ester (7a) To a solution of KOH (7.21 g, 110 mmol) in H 2 O (20 ml), was added 5-phenyl-1,3-cyclohexanedione (20.8 g, 110 mmol), and the mixture was stirred at room temperature for 15 min. Ethyl 2-chloroacetoacetate (15.2 ml, 110 mmol) in MeOH (40 ml) was added, and the mixture was stirred for 20 h at room temperature. AcOH (62 ml) was added, and the reaction mixture was heated under reflux for 3 h and then the solvent was removed. The mixture was diluted with EtOAc, and washed with saturated aqueous NaHCO 3 and brine. The organic phase was dried over Na 2 SO 4 3-Methyl-4-oxo-6-phenyl-4,5,6,7-tetrahydro-1H-indole-2-carboxylic Acid Ethyl Ester (8a) To a solution of ethyl acetoacetate (15.0 g, 93.8 mmol) in AcOH (30 ml), was added a solution of NaNO 2 (8.00 g, 116 mmol) in H 2 O (25 ml) below 12°C, and the mixture was stirred at such a rate that the temperature remained below 12°C for 3 h and was left at room temperature overnight. A solution of 5-phenyl-1,3-cyclohexanedione (24.0 g, 128 mmol) in AcOH (60 ml) was added. Then the zinc dust (16.7 g, 255 mmol) was added at such a rate that the temperature did not rise above 60°C. After stirring for 0.5 h and refluxing for 3 h, the solution was separated from the excess zinc dust and poured into iced water (500 ml) to give a yellow solid. The crude product was purified by recrystallization from ben- Butyldimethylsilanyloxy)-3-methyl-6-phenyl-4,5,6 ,7-tetrahydrobenzofuran-2-carboxylic Acid Ethyl Ester (11) tert-Butyldimethylsilyl chloride (80 mg, 0.533 mmol) was added to a stirred solution of 10 (79 mg, 0.267 mmol) and imidazole (55 mg, 0.800 mmol) in DMF (1.0 ml) at room temperature. The mixture was stirred for 40 h at room temperature. The reaction mixture was diluted with EtOAc, and washed with 10% aqueous KHSO 4 , saturated aqueous NaHCO 3 and brine. The organic phase was dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by flash column chromatography (hexane : EtOAcϭ4 : 1 as a solvent) to give 104 mg (95%) of 11 as a colorless oil. 0.566 mmol) in THF (1.0 ml) at Ϫ78°C under N 2 . The mixture was stirred for 30 min at the same temperature. After 12 (81 mg, 0.189 mmol) in THF (1.0 ml) was added to the reaction mixture over 5 min at Ϫ78°C, the reaction mixture was stirred for 30 min at the same temperature. The reaction mixture was quenched with saturated aqueous NH 4 Cl, and extracted with EtOAc. The extract was washed with brine, dried over Na 2 SO 4 4-Dimethoxyphenyl)-(4-hydroxy-3-methyl-6-phenyl-4,5,6 ,7-tetrahydrobenzofuran-2-yl)methanone (14) To a stirred solution of 13 (62 mg, 0.122 mmol) in THF (1.0 ml) was added n-Bu 4 NF (0.244 ml, 1.0 M solution in THF) and AcOH (14 ml, 0.244 mmol) at room temperature. The mixture was stirred for 14 h at room temperature. The n-Bu 4 NF (0.488 ml, 1.0 M solution in THF) and AcOH (28 ml, 0.488 mmol) were added to the reaction mixture, and stirred for 1 h at 60°C. The reaction mixture was diluted with EtOAc, and washed with H 2 O, saturated aqueous NaHCO 3 and brine. The organic phase was dried over Na 2 SO 4 
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